Research Advances in the Treatment of Melanoma by Treat Melanoma

Author(s): Can Liu, Si-Qi He, Xiao-Qing Chen, Hui-Qing Xie, Yong Chen, Rui Liu, Ke Cao, Jian-Da Zhou

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 2 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Melanoma is a highly malignant tumor. Prognoses of melanoma patients are often unsatisfactory due to poor operational and chemoradiational efficacy. Recently, researches for melanoma treatment have found multipeptide vaccines a favorite and possible breakthrough as they are stable in chemical property and easy to be synthesized, have no carcinogenecity and dispense with virus vector. Studies have shown that the immunogenicity of multipeptide vaccines could be enhanced by use of immunoadjuvants, joining dendritic cells (DCs), full-length or epitope-superposited antigen peptides, costimulatory molecules and cellpenetrating peptides fusion, thereby improving anti-tumor effect. Certain achievements have been obtained in clinical treatment of melanoma by multipeptide vaccines, but problems including poor immunogenicity and human leukocyte antigen (HLA) phenotype restriction may require further study.

Keywords: Immunogenicity, Melanoma, Multipeptide vaccines, Melanoma-Associated protein 100, Survivin, Immune adjuvants.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 21 September, 2015
Page: [242 - 250]
Pages: 9
DOI: 10.2174/1568026615666150812121439
Price: $65

Article Metrics

PDF: 24